Kaneka Eurogentec will manufacture INOVIO’s DNA vaccine candidate against COVID-19

LIEGE, BE – December 3rd, 2020 – Kaneka Eurogentec S.A. (KEGT), a custom service and FDA inspected Contract Development and Manufacturing Organization (CDMO) is proud to announce today the execution of an agreement with INOVIO to manufacture COVID-19 DNA vaccine candidate – INO-4800.

INOVIO has assembled a global coalition of collaborators, partners and funders to rapidly advance the development of INO-4800, a DNA vaccine against the novel coronavirus SARS-CoV-2.

INOVIO’s President & CEO, Dr. J. Joseph Kim, said, “Our partnership with Kaneka Eurogentec, one of the world’s largest and most experienced plasmid manufacturers, provides additional scale to our growing global manufacturing coalition. Kaneka Eurogentec will be a crucial member of INOVIO’s global manufacturing consortium, supporting our plans to produce, manufacture and scale our COVID-19 candidate, INO-4800.”

Dr. Lieven Janssens, Kaneka Eurogentec’s President and CEO, said, “We are excited to join INOVIO’s growing global manufacturing consortium and look forward to supporting the manufacturing needs of DNA medicines and vaccines across INOVIO’s platform. We are pleased that our large-scale manufacturing technologies are well recognized by INOVIO, a leading player in the DNA plasmid field.”

KANEKA EUROGENTEC will manufacture large quantity of DNA vaccine against COVID-19

KANEKA EUROGENTEC is considered as the world leader in Kg-scale biomanufacturing of GMP DNA plasmid for gene and cell therapies. DNA plasmid is the active pharmaceutical
ingredient of DNA vaccines, as well as the key starting material of mRNA, new generations of vaccines.

INOVO’s Senior Vice President of Biological Manufacturing and Clinical Supply Management, Robert J. Juba Jr., said, “Kaneka Eurogentec brings a wealth of DNA plasmid manufacturing expertise and innovation to INOVO’s global consortium to manufacture INO-4800. We look forward to working with them to utilize their state-of-the-art, large-scale manufacturing capabilities towards our goal of producing hundreds of millions of doses of INO-4800 for worldwide distribution.”

KANEKA EUROGENTEC will manufacture INO-4800 – DNA vaccine in its new state-of-the-art GMP facilities. These contain a brand new 2200 L fermentor to achieve high volumes of vaccine.

Kaneka Eurogentec plans to recruit 80 new colleagues to support the production activities related to COVID-19 vaccines.

Clinical trials in progress

INOVO is conducting a Phase 2 segment of its planned Phase 2/3 clinical trial for INO-4800, its COVID-19 vaccine candidate. The planned Phase 2/3 clinical trial, called INNOVATE (Inovio INO-4800 Vaccine Trial for Efficacy), is a randomized, blinded, placebo-controlled safety and efficacy trial of INO-4800 to be conducted in adults in the U.S. The INNOVATE trial will be funded by the U.S. Department of Defense.

About INOVO

INOVO is a leading company in DNA medicines with 15 DNA medicine clinical programs currently in development focused on HPV-associated diseases, cancer, and infectious diseases, including coronaviruses associated with MERS and COVID-19 diseases.

INOVO has extensive experience working with coronaviruses and was the first company with a Phase 2 vaccine for a related coronavirus that causes Middle East Respiratory Syndrome (MERS).

For more information, visit www.inovio.com.
About Kaneka Eurogentec

Eurogentec was founded in 1985 as a spin-off company of the University of Liège (Belgium). Kaneka Eurogentec contributes to improving health and fighting diseases by supplying products and services to scientists involved in life science research, molecular diagnostics, and therapeutic developments.

The Liège-based company is recognized as one of the major suppliers in the field of genomics and proteomics as well as a trusted US FDA inspected Contract Development and Manufacturing Organization (CDMO) for the bio-production of pharmaceutical vaccines and medicines.

Kaneka Eurogentec is a leading company in large scale production of GMP DNA plasmid for DNA vaccines and starting materials for vector-based gene medicines. In parallel, Kaneka Eurogentec offers CDMO services for GMP mRNA, the active molecule of RNA vaccines and RNA based gene therapy.

DNA and RNA therapies are very promising new technologies to prevent and treat diseases such as pandemics, orphan diseases, cancers, infectious diseases and genetic disorders.

In 2010, Eurogentec, renamed Kaneka Eurogentec in April 2017, became part of Kaneka Corporation, a large Japanese chemical company focusing on technology and innovation.

For more information, visit https://www.eurogentec.com/

About Kaneka Corporation

Kaneka is an innovation-oriented chemical company. Traditionally the company has been active in polymers, fermentation, biotechnology and electronics, as well as other fields. Business activities now span a broad spectrum of markets ranging from plastics, EPS resins, chemicals and foodstuffs to pharmaceuticals, medical devices, electrical and electronic materials and synthetic fibers.
The life science related activities are currently one of the strategically important domains for Kaneka. The company has been a pioneer among Japanese chemical companies in establishing overseas operations, beginning in 1970 with a subsidiary in Belgium.

For more information, visit https://www.kaneka.co.jp/en/

Download the Official INOVIO’s Press Release:


Contact Info

Frederic Dimola
Global Marketing & Communication Manager

T. +32 496 74 51 57
f.dimola@eurogentec.com